Press release
Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma
DelveInsight's "Single Ventricle Heart Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Single Ventricle Heart Disease, historical and forecasted epidemiology as well as the Single Ventricle Heart Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Single Ventricle Heart Disease, offering comprehensive insights into the Single Ventricle Heart Disease revenue trends, prevalence, and treatment landscape. The report delves into key Single Ventricle Heart Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Single Ventricle Heart Disease therapies. Additionally, we cover the landscape of Single Ventricle Heart Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Single Ventricle Heart Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Single Ventricle Heart Disease space.
To Know in detail about the Single Ventricle Heart Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Single Ventricle Heart Disease Market Forecast [https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Single Ventricle Heart Disease Market Report:
*
The Single Ventricle Heart Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
*
In July 2025, Mezzion Pharmaceuticals, Inc., the U.S. arm of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company dedicated to advancing treatments for rare and underserved conditions. Based in New Jersey, the company is spearheading the global clinical development and commercialization of JURVIGO Registered (udenafil), an investigational therapy in Phase 3 trials for individuals with single ventricle heart disease and Fontan physiology. JURVIGO Registered has been granted Rare Pediatric Disease Designation by the U.S. FDA, and Mezzion plans to submit a New Drug Application (NDA) upon completion of the FUEL-2 trial.
*
In September 2024, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, has announced top-line results for EDG-7500 from its Phase 1 trial in healthy participants and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). EDG-7500 is an innovative oral, selective cardiac sarcomere modulator developed to reduce early contraction velocity and improve impaired cardiac relaxation linked to HCM.
*
Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others
*
Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others
*
The Single Ventricle Heart Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Single Ventricle Heart Disease pipeline products will significantly revolutionize the Single Ventricle Heart Disease market dynamics.
*
The analysis of single ventricle heart disease revealed that these defects are uncommon, affecting approximately five in every 100,000 newborns. They are also among the most complex heart conditions, typically necessitating at least one surgical intervention.
*
The analysis found that the most prevalent congenital heart defects (ACHDs) include atrial septal defect (20.5%), ventricular septal defect (20.5%), tetralogy of Fallot (12.9%), and univentricular heart (UVH)/single ventricle (SV) (6.6%).
*
It was discovered that hypoplastic left heart syndrome, the most prevalent type of univentricular heart disease, occurs in 2 to 3 out of every 10,000 births, with a higher incidence in males.
*
The analysis revealed that double outlet right ventricle occurs in 0.009 cases per 10,000 live births, while double inlet left ventricle is seen in up to 0.01 cases per 10,000 live births.
*
The analysis found that tricuspid atresia occurs in approximately 1 in every 10,000 live births, while Ebstein anomaly is seen in about 0.5 per 10,000 live births, with a noted gender preference.
Single Ventricle Heart Disease Overview
Single Ventricle Heart Disease is a rare congenital heart defect where one of the heart's ventricles is underdeveloped or missing. This condition disrupts the normal flow of blood, as the heart cannot effectively pump oxygenated blood to the body and deoxygenated blood to the lungs.
Get a Free sample for the Single Ventricle Heart Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market [https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Single Ventricle Heart Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Single Ventricle Heart Disease Epidemiology Segmentation:
The Single Ventricle Heart Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Single Ventricle Heart Disease
*
Prevalent Cases of Single Ventricle Heart Disease by severity
*
Gender-specific Prevalence of Single Ventricle Heart Disease
*
Diagnosed Cases of Episodic and Chronic Single Ventricle Heart Disease
Download the report to understand which factors are driving Single Ventricle Heart Disease epidemiology trends @ Single Ventricle Heart Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Single Ventricle Heart Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Single Ventricle Heart Disease market or expected to get launched during the study period. The analysis covers Single Ventricle Heart Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Single Ventricle Heart Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Single Ventricle Heart Disease Therapies and Key Companies
*
Udenafil: Mezzion Pharma Co
*
AZD1305: AstraZeneca
*
Bosentan: Rigshospitalet
*
Captopril: Astrazeneca
*
BAY1142524: Bayer
*
QVA149: Novartis
*
Ivabradine: Amgen
*
REGN5381: Regeneron Pharma
*
Macitentan: Actelion
*
JRM-001: Metcela
Discover more about therapies set to grab major Single Ventricle Heart Disease market share @ Single Ventricle Heart Disease Treatment Landscape [https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Single Ventricle Heart Disease Market Drivers
*
Increasing Awareness and Early Diagnosis
*
Advancements in Surgical Techniques
*
Growing Focus on Pediatric Cardiology
*
Development of Novel Therapies
*
Supportive Government Initiatives
*
Improved Post-Surgical Care
*
Increasing Healthcare Accessibility
Single Ventricle Heart Disease Market Barriers
*
High Treatment Costs
*
Limited Awareness in Low-income Regions
*
Complexity of Treatment
*
Long-term Health Risks
*
Challenges in Personalized Medicine
*
Risk of Heart Transplantation
*
Limited Market Size
Scope of the Single Ventricle Heart Disease Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others
*
Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others
*
Single Ventricle Heart Disease Therapeutic Assessment: Single Ventricle Heart Disease current marketed and Single Ventricle Heart Disease emerging therapies
*
Single Ventricle Heart Disease Market Dynamics: Single Ventricle Heart Disease market drivers and Single Ventricle Heart Disease market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Single Ventricle Heart Disease Unmet Needs, KOL's views, Analyst's views, Single Ventricle Heart Disease Market Access and Reimbursement
To know more about Single Ventricle Heart Disease companies working in the treatment market, visit @ Single Ventricle Heart Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Single Ventricle Heart Disease Market Report Introduction
2. Executive Summary for Single Ventricle Heart Disease
3. SWOT analysis of Single Ventricle Heart Disease
4. Single Ventricle Heart Disease Patient Share (%) Overview at a Glance
5. Single Ventricle Heart Disease Market Overview at a Glance
6. Single Ventricle Heart Disease Disease Background and Overview
7. Single Ventricle Heart Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Single Ventricle Heart Disease
9. Single Ventricle Heart Disease Current Treatment and Medical Practices
10. Single Ventricle Heart Disease Unmet Needs
11. Single Ventricle Heart Disease Emerging Therapies
12. Single Ventricle Heart Disease Market Outlook
13. Country-Wise Single Ventricle Heart Disease Market Analysis (2020-2034)
14. Single Ventricle Heart Disease Market Access and Reimbursement of Therapies
15. Single Ventricle Heart Disease Market Drivers
16. Single Ventricle Heart Disease Market Barriers
17. Single Ventricle Heart Disease Appendix
18. Single Ventricle Heart Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=single-ventricle-heart-disease-market-dynamics-indicate-upward-trajectory-through-2034-reports-delveinsight-mezzion-pharma-astrazeneca-rigshospitalet-bayer-novartis-amgen-regeneron-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma here
News-ID: 4152462 • Views: …
More Releases from ABNewswire
Oil-quenched steel wire: the "hidden champion" material in the industrial field
Among the many metal materials, there's a seemingly ordinary yet crucial product: oil-quenched steel wire.
Image: https://ecdn6.globalso.com/upload/p/2550/image_other/2025-08/oil-quenched-steel-wire-2.jpg Image: https://ecdn6.globalso.com/upload/p/2550/image_other/2025-08/oil-quenched-steel-wire-2.webp
While it may not be widely known, it plays an irreplaceable role in a wide range of fields, including automotive, machinery, and construction. Today, we'll take a closer look at this "hidden champion" material.
. What is Oil-Quenched Steel Wire? [https://www.steelfsd.com/factory-quality-prestressed-steel-wire-for-concrete-product/]
Oil-quenched steel wire [https://www.steelfsd.com/factory-quality-prestressed-steel-wire-for-concrete-product/] is steel wire that has been oil-quenched and tempered. This…
SRK 800 RR: Precision Unleashed - Conquer Every Curve, Command Every Straight
Dominate the track with SRK 800 RR [https://global.qjmotor.com/car.html?id=84] where razor-sharp styling meets relentless performance. Every curve conquered, every straight commanded. Born to rule the road.
Image: https://www.abnewswire.com/upload/2025/08/18d883d1e49d9405cabeac28a80a90db.jpg
Image: https://www.abnewswire.com/upload/2025/08/4cc3e1403b15be9fad62c33e883644d4.jpg
Image: https://www.abnewswire.com/upload/2025/08/cbda930e1dd759bf374f9deea0f7661c.jpg
Image: https://www.abnewswire.com/upload/2025/08/d4002bb8e74dd3fd17c88539e5ef3f70.jpg
Image: https://www.abnewswire.com/upload/2025/08/a6d33dd4e22eb939cb93b7eef5ab451b.jpg
Visit QJMOTOR's Global Website
Excited to learn more about QJMOTOR? You can visit their global website at QJMOTOR Global [https://global.qjmotor.com/]. There, you'll find more information about their latest products, partnerships, and innovations.
With a long history, QJMOTOR [file:///C:/Users/Mihai/Desktop/7.28-8.1%E9%92%B1%E6%B1%9F%E6%8E%A8%E6%96%87/%C2%A0https:/global.qjmotor.com/] has accumulated rich experience in…
SRK 600 RS: Born for the Bend - Where Racing DNA Meets Mountain Mastery
Alone on the mountain tracks, SRK 600 RS [https://global.qjmotor.com/car.html?id=87] masters every turn with racing DNA, precise control and relentless spirit as if it was born there. Road curves. It dominates.
Image: https://www.abnewswire.com/upload/2025/08/4d45fd2418a9bd183630e9dc0d7057a6.jpg
Image: https://www.abnewswire.com/upload/2025/08/98197907882ea0c550a34e4074647c7c.jpg
Image: https://www.abnewswire.com/upload/2025/08/bce067cf6840e17ebac26b84f9511d2f.jpg
Visit QJMOTOR's Global Website
Excited to learn more about QJMOTOR? You can visit their global website at QJMOTOR Global [https://global.qjmotor.com/]. There, you'll find more information about their latest products, partnerships, and innovations.
With a long history, QJMOTOR [file:///C:/Users/Mihai/Desktop/7.28-8.1%E9%92%B1%E6%B1%9F%E6%8E%A8%E6%96%87/%C2%A0https:/global.qjmotor.com/] has accumulated…
Hop On The ATR 300 And Feel The Pulse Of The Ride
Hop on the ATR 300 [https://global.qjmotor.com/] and feel the pulse of the ride - small, nimble, yet full of energy. Weave through every trail with ease as light as the wind. Twists spark joy and bends breathe freedom.
Image: https://www.abnewswire.com/upload/2025/08/333d93d739f3d6f892bfe3b37c6773ee.jpg
Image: https://www.abnewswire.com/upload/2025/08/bc17fbb7a70edf4afb6abb154ba616d1.jpg
Image: https://www.abnewswire.com/upload/2025/08/831dfbbc6885ae7e5ec89cb54a304daf.jpg
Visit QJMOTOR's Global Website
Excited to learn more about QJMOTOR? You can visit their global website at QJMOTOR Global [https://global.qjmotor.com/]. There, you'll find more information about their latest products, partnerships, and…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
